25 To 99 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.3)
-
Patent number: 8748367Abstract: The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic stem cell, adult stem cell, progenitor cell and/or a cell derived from a stem cell or progenitor cell, for treating a condition characterized by or associated with loss and/or gain of cells. In a preferred embodiment, the condition is a neurotrauma or a condition or disease of the CNS and/or PNS and/or ANS, for example, Alzheimer's disease.Type: GrantFiled: February 26, 2010Date of Patent: June 10, 2014Assignee: AS Faktor ABInventors: Hans-Arne Hansson, Eva Jennische, Stefan Lange, Ivar Lönnroth, Peter Eriksson, Anders Persson
-
Patent number: 8748373Abstract: A polypeptide comprising a preS1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the preS2 region of HBV or a fragment thereof, and methods of use to inhibit virus infection are disclosed. A lentivirus comprising hepatitis B virus (HBV) envelope proteins, or a fragment thereof, and/or the L envelope protein of HBV and/or the M envelope protein of HBV or a fragment thereof, and/or the S envelope protein of HBV or a fragment thereof, and methods of use of this lentivirus HBV pseudovirus as a gene therapy to target hepatocytes for the administration of therapeutic agents are also disclosed.Type: GrantFiled: February 20, 2008Date of Patent: June 10, 2014Assignee: Fox Chase Cancer CenterInventors: Ning Chai, John M. Taylor
-
Patent number: 8748395Abstract: Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are described.Type: GrantFiled: September 12, 2006Date of Patent: June 10, 2014Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Patent number: 8748571Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: October 20, 2011Date of Patent: June 10, 2014Assignee: Amgen Inc.Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
-
Patent number: 8748386Abstract: The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.Type: GrantFiled: June 10, 2010Date of Patent: June 10, 2014Assignee: New York UniversityInventor: Einar M. Sigurdsson
-
Patent number: 8748375Abstract: Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.Type: GrantFiled: March 17, 2010Date of Patent: June 10, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Christine M. Mack, Jonathan David Roth
-
Patent number: 8748394Abstract: A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a synthetic apolipoprotein A-1 (Apo A-I) mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including a synthetic apolipoprotein A-I (Apo A-I) mimetic peptide, or combination of an Apo A-I synthetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of an endogenous Apo A-I related peptide. A composition including an apolipoprotein A-1 (Apo A-I) synthetic peptide in a form suitable for delivery into a blood vessel, the peptide including an amino acid backbone that has less amino acid residues relative to endogenous Apo A-I and a chimera of helix 1 and helix 9 of Apo A-I.Type: GrantFiled: February 22, 2013Date of Patent: June 10, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventors: Katsuyuki Murase, Li Zhao, Irina Astafieva, Paul M. Consigny
-
Publication number: 20140155314Abstract: Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.Type: ApplicationFiled: June 13, 2012Publication date: June 5, 2014Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Yulia A. Komarova, Uzma Saqib, Stephen M. Vogel, Asrar B. Malik
-
Patent number: 8741836Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: GrantFiled: June 8, 2012Date of Patent: June 3, 2014Assignee: Novo Nordisk A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Patent number: 8741842Abstract: This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without inducing excessive hypotension. This document also provides methods and materials for inducing natriuretic activities within a mammal.Type: GrantFiled: June 16, 2009Date of Patent: June 3, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: John C. Burnett, Jr., Candace Y. W. Lee
-
Patent number: 8741847Abstract: A method for treating an autism spectrum condition includes administering an effective dose of a TNF-? inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-? in the cerebrospinal fluid or elevated TNF-? in the serum. A TNF-? inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.Type: GrantFiled: May 4, 2012Date of Patent: June 3, 2014Inventor: Michael Chez
-
Publication number: 20140148397Abstract: An engineered polypeptide comprising an AgRP analog with increased basic residues compared to the wild type polypeptide, wherein the polypeptide, when introduced into the CNS of a mammal, stimulates appetite.Type: ApplicationFiled: July 4, 2012Publication date: May 29, 2014Inventors: Michael E. Madonna, Stephen Benoit, Glenn L. Millhauser
-
Patent number: 8735353Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence from thrombin, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 7, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: GrantFiled: September 22, 2010Date of Patent: May 27, 2014Assignee: XMedic ABInventors: Martina Kalle, Gopinath Kasetty, Nils Martin Malmsten, Praveen Papareddy, Artur Schmidtchen, Bjorn Ulrik Walse
-
Publication number: 20140142049Abstract: The invention provides compositions and methods for treating a disease or disorder associated with Apelin. Specifically, the invention relates to a pegylated form of Apelin to provide extended circulating life and inotropic effects, and thereby efficiently treat diseases or disorders associated with Apelin.Type: ApplicationFiled: March 8, 2012Publication date: May 22, 2014Inventors: Zhiqiang Jia, Lihui Hou, Clark Q Pan, Geoffrey Akita
-
Patent number: 8729029Abstract: The invention relates to peptide derivatives (peptides and pseudo-peptides) and use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides and prodrug conjugates of the invention can be used to vectorise molecules of pharmaceutical or diagnostic interest, such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes, and notably to promote their transport across the blood-brain barrier (BBB).Type: GrantFiled: October 20, 2009Date of Patent: May 20, 2014Assignees: Vect-Horus, Centre National de la Recherche Scientifique, Universite d'Aix-MarseilleInventors: Michel Khrestchatisky, Marion David, Yves Molino, Patrick Vlieghe
-
Publication number: 20140134188Abstract: The invention provides for a method for screening compounds that bind to and modulate the hair-specific G-protein coupled receptor, P2RY5. The invention farther provides for methods for controlling hair growth by administering a P2RY5 modulating compound to a subject.Type: ApplicationFiled: September 30, 2013Publication date: May 15, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventor: Angela M. Christiano
-
Patent number: 8716241Abstract: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes and also provides methods for treating patients with type I diabetes and for limiting pancreatic beta cell apoptosis. The present invention also provides methods for diagnosing type I diabetes or a propensity to develop type I diabetes and methods for identifying diabetic patients to be treated with anti-apoCIII therapy.Type: GrantFiled: July 5, 2013Date of Patent: May 6, 2014Assignee: BioCrine ABInventor: Per-Olof Berggren
-
Patent number: 8716228Abstract: Use of a GPR54 agonist or antagonist for the treatment of a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, and/or for treatment of depression, and/or for improving cognitive function is disclosed. In particular, the invention relates to the use of kisspeptin or a peptide thereof for the treatment of schizophrenia.Type: GrantFiled: May 27, 2010Date of Patent: May 6, 2014Assignee: YEDA Research and Development Co. Ltd.Inventors: Michal Eisenbach-Schwartz, Gil M Lewitus, Michal Cardon-Yaakov, Noga Ron-Harel
-
Publication number: 20140120169Abstract: A process for preparing polymeric composite particles includes the steps of preparing an oil phase containing a biodegradable polymer and a water phase containing a hydrophilic compound or nanoparticle and emulsifying the oil phase in the water phase to form emulsions. Then solvent is removed from the emulsions to prepare the particles in the form of capsules and spheres in sizes from 0.01 ?m (10 nm) to 50 ?m.Type: ApplicationFiled: October 24, 2013Publication date: May 1, 2014Applicant: Board of Trustees of Michigan State UniversityInventors: Ilsoon Lee, Shaowen Ji
-
Publication number: 20140120156Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.Type: ApplicationFiled: September 6, 2013Publication date: May 1, 2014Inventors: Vincent Craig BOND, Michael POWELL, MingBo HUANG, Syed ALI
-
Patent number: 8709995Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: August 20, 2007Date of Patent: April 29, 2014Assignees: Geron Corporation, The Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 8710017Abstract: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.Type: GrantFiled: November 1, 2011Date of Patent: April 29, 2014Assignee: Board of Regents, The University of Texas SystemsInventors: Wadih Arap, Renata Pasqualini
-
Patent number: 8710007Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.Type: GrantFiled: November 22, 2010Date of Patent: April 29, 2014Assignee: Dyax Corp.Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
-
Patent number: 8710008Abstract: A peptide comprising a unit of formula (I) and having a molecular weight of less than 2000 wherein each X is independently an organic group, e.g. a C1-6 alkyl or C1-6 alkenyl group, preferably —CH2—CH?CH2, or the two X groups taken together can form a covalent or non-covalent link between the two O groups, preferably a C1-10 saturated or unsaturated carbon chain optionally interrupted by one or more heteroatoms selected from O, S, N, P, or Si, especially a C3-10 carbon chain or one X represents an azido group and the other an C2-6-alkynyl group; both Z's are the same and are O or S; each Y is independently C, CH, CH2, N or NH; R1 is H or C1-6 alkyl; R2 is H or C1-6 alkyl; R5 is a C1-6 alkyl group, preferably isopropyl; or a salt, ester or prodrug thereof.Type: GrantFiled: December 22, 2009Date of Patent: April 29, 2014Assignee: Universitetet I OsloInventors: Oyvind Jacobsen, Jo Klaveness, Pal Rongved, Mahmood Amiry-Moghaddam, Ole Petter Ottersen
-
Patent number: 8710005Abstract: A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide.Type: GrantFiled: April 12, 2010Date of Patent: April 29, 2014Assignee: Toagosei Co., Ltd.Inventors: Tetsuhiko Yoshida, Nahoko Kobayashi
-
Patent number: 8703910Abstract: Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic solvent or other adjuvant to the dried peptide, followed by the addition of either: 1) a polar organic solvent, with or without water, (where a polar aprotic solvent is added first) or 2) a polar aprotic solvent or other adjuvant to the peptide polar organic solvent (where the polar organic solvent is added first), to the peptide formulation.Type: GrantFiled: February 15, 2013Date of Patent: April 22, 2014Assignee: Vestaron CorproationInventors: William Tedford, John McIntyre, Daniel Russell, Peter Carlson
-
Patent number: 8703708Abstract: Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.Type: GrantFiled: March 18, 2010Date of Patent: April 22, 2014Assignees: The Brigham and Women's Hospital, Inc., Cincinnati Children's Hospital Medical CenterInventors: Jeremy Duffield, Richard A. Lang
-
Patent number: 8703698Abstract: Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.Type: GrantFiled: February 8, 2010Date of Patent: April 22, 2014Assignee: The University of ChicagoInventors: Robert Kisilevsky, Shui-Pang Tam, John B. Ancsin, Zongchao Jia
-
Publication number: 20140107043Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.Type: ApplicationFiled: March 16, 2012Publication date: April 17, 2014Inventors: Françoise Baleux, Hugues Lortat-Jacob, David Bonnaffe
-
Patent number: 8697632Abstract: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: GrantFiled: December 18, 2009Date of Patent: April 15, 2014Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, Binbin Kou, Shujiang Cheng
-
Patent number: 8697081Abstract: The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent.Type: GrantFiled: April 8, 2009Date of Patent: April 15, 2014Assignee: The Regents of the University of MichiganInventors: Stephen J. Weiss, Robert G. Rowe
-
Patent number: 8697654Abstract: Short single chain peptides having affinity for a target surface often lack the binding durability required for certain commercial applications. One way to improve durability is to promote multivalent binding by linking together binding sequences using peptide linkers. However, the resulting single chain binding peptides often suffer from linker entropy. It has been discovered that the use of rigid peptide linkers when linking together multiple binding sequences enhances the binding affinity of the resulting single chain peptide.Type: GrantFiled: December 8, 2009Date of Patent: April 15, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Qiong Cheng, Stephen R. Fahnestock, Hongxian He, Kristy N. Kostichka, Hong Wang
-
Patent number: 8691771Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: GrantFiled: May 20, 2011Date of Patent: April 8, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Patent number: 8691755Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.Type: GrantFiled: May 4, 2012Date of Patent: April 8, 2014Assignee: Cebix ABInventors: Sheri Barrack, James Callaway, Michelle Mazzoni
-
Publication number: 20140094409Abstract: Brain prorenin and the (pro)renin receptor (PRR) have a functional role in the development of hypertension. The present disclosure presents functional PRR antagonistic peptides (e.g., PR10, PR20, PR30, and PR40). In addition, modified peptides comprising one or more thioether-bridges that are stable and strong PRR antagonists are also provided. Methods for treating and preventing hypertension, including neurogenic hypertension, and diabetes with a PRR antagonist are also provided.Type: ApplicationFiled: September 19, 2013Publication date: April 3, 2014Inventor: Yumei FENG
-
Patent number: 8685928Abstract: The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.Type: GrantFiled: February 14, 2011Date of Patent: April 1, 2014Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC.Inventors: Donald W. Kufe, Surender Kharbanda
-
Patent number: 8685404Abstract: Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II ?1 domain and the second domain is an MHC class II ?1 domain; or wherein the first domain is an MHC class I ?1 domain and the second domain is an MHC class I ?2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system.Type: GrantFiled: January 30, 2012Date of Patent: April 1, 2014Assignees: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans AffairsInventors: Jennifer Loftis, Marilyn Huckans, Arthur A. Vandenbark
-
Patent number: 8685433Abstract: The present invention provides an absorbable coating for an implantable device and the methods of making and using the same.Type: GrantFiled: March 31, 2010Date of Patent: April 1, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventors: Lothar W. Kleiner, Syed F. A. Hossainy, Mikael Trollsas, Stephen D. Pacetti
-
Publication number: 20140087995Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicant: NOVO NORDISK A/SInventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
-
Publication number: 20140088024Abstract: The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and antibodies, and methods for the prevention and treatment of conditions, diseases and disorders that would be improved, eased, or lessened by the administration of a composition of the invention, including but not limited to glucose metabolism diseases.Type: ApplicationFiled: November 20, 2013Publication date: March 27, 2014Applicant: AUCKLAND UNISERVICES LIMITEDInventors: Christina Maree BUCHANAN, Garth James Smith COOPER
-
Patent number: 8680058Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.Type: GrantFiled: November 2, 2010Date of Patent: March 25, 2014Assignees: The Regents of the University of California, C3 Jian, Inc.Inventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Maxwell H. Anderson, Fengxia Qi, Jian He, Ian H. McHardy
-
Patent number: 8673856Abstract: The present invention relates to a method for increasing the binding reversibility of a ?-conotoxin to a N-type calcium channel, which comprises preparing a ?-conotoxin having a Ile and/or Ala residue at a position of amino acid (11 and/or 12), respectively in the second loop between cysteine residues (2 and 3) of the ?-conotoxin represented by the formula I, such that the prepared ?-conotoxin has the increased binding reversibility to N-type calcium channel. In addition, the present invention relates to a novel ?-conotoxin and a pharmaceutical composition having plausible properties in view of blocking activity to and specificity to N-type calcium channel, and dramatically improved binding reversibility to N-type calcium channel.Type: GrantFiled: November 2, 2007Date of Patent: March 18, 2014Assignee: Anygen Co., Ltd.Inventors: Jae II Kim, Hye Whon Rhim, Hyun Jeong Kim, Hong Won Suh, Soung Hun Roh, Jung A Yun, Seung Kyu Lee, Young Jae Eu, Heung Sik Na
-
Patent number: 8673860Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.Type: GrantFiled: February 3, 2010Date of Patent: March 18, 2014Assignee: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-wel Wang, Benjamin Spink, Willem P. Stemmer, Nathan C. Geething, Wayne To, Jeffrey L. Cleland
-
Publication number: 20140073577Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7 and/or Nav1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 16, 2012Publication date: March 13, 2014Applicant: AMGEN INC.Inventors: Justin K. Murray, Leslie P. Miranda, Stefan I. McDonough
-
Publication number: 20140073555Abstract: A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).Type: ApplicationFiled: June 26, 2013Publication date: March 13, 2014Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jose Courty, Ara Hovanessian, Jean Paul Briand, Gilles Guichard, Yamina Hamma
-
Publication number: 20140066384Abstract: Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides are collateral vessel endothelia (CVE) homing polypeptides, which have been shown to home to collateral vessel endothelia after ischemia.Type: ApplicationFiled: April 15, 2013Publication date: March 6, 2014Applicants: MedStar Health Research Institute, Inc., Georgetown UniversityInventors: Anton Wellstein, Marcel O. Schmidt, Stephan Zbinden, Mary Susan Burnett, Stephen E. Epstein
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Publication number: 20140065175Abstract: The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.Type: ApplicationFiled: February 17, 2012Publication date: March 6, 2014Inventors: M. Covadonga Alonso Martí, José Ángel Martínez Escribano
-
Publication number: 20140066376Abstract: Provided herein are compositions and methods related to promoting protection or repair of articular cartilage and/or musculoskeletal soft tissue by contacting the cartilage, tissues or cellular components thereof with a parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor agonist or releasing factor.Type: ApplicationFiled: August 20, 2013Publication date: March 6, 2014Applicant: UNIVERSITY OF ROCHESTERInventors: Randy N. Rosier, Michael J. Zuscik, Erik Sampson, Susan V. Bukata, J. Edward Puzas, Hani Awad
-
Patent number: 8663617Abstract: The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.Type: GrantFiled: October 16, 2012Date of Patent: March 4, 2014Assignee: Tufts UniversityInventor: Ira M Herman